Cabot (CBT) Stock: Buy, Sell, or Hold?
CBT - Cabot Corporation
$79.68
0.89 (1.13%)
▲
5d:
-1.86%
30d:
-7.67%
90d:
-6.76%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 02, 2026
Get Alerted When CBT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CBT shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CBT shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$108.17
Based on 6.9% avg growth
INTRINSIC VALUE TODAY
$67.16
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CBT is currently trading at $79.68, which is considered oversold relative to its 30-day fair value range of $81.28 to $86.49. The stock's valuation (Forward PE: 11.4) is in line with its historical norms (11.1). At these levels, the market is pricing in 0.7% annual earnings growth.
Technical Outlook: Technically, CBT is in a uptrend. The price is currently testing key support at $77.68. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CBT scores 21/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $91.33 (+14.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CBT is in a uptrend. The price is currently testing key support at $77.68. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CBT scores 21/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $91.33 (+14.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$81.28 -
$86.49
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
58.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (21/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($91.33)
- BULLISH: Expecting earnings turnaround to 0.7% growth with 6.4% revenue growth
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$81.28 -
$86.49
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$77.68
Resistance Level
$85.60
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.40
Wall Street Target
$91.33
(+14.6%)
Revenue Growth (YoY)
6.4%
Earnings Growth (YoY)
-93.7%
Profit Margin
5.2%
Valuation Premium vs History
+0.7% premium
PE vs Historical
11.4 vs 11.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.7%
(market-implied from PE analysis)
1-Year Target
$80.24
(+1%)
2-Year Target
$80.80
(+1%)
3-Year Target
$81.37
(+2%)
3-Yr Target (if PE normalizes)
(PE: 11→11)
PE COMPRESSION
$79.19
(-1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 9.8%)
$186.79
(+134%)
Base:
(SPY PE: 11.4, Growth: 9.8%)
$105.61
(+33%)
Bear:
(PE: 9.7, Growth: 9.8%)
$89.77
(+13%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (22x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 22.19 | Current EPS (TTM): $3.55
Bull Case
$170.58
(+114%)
Analyst growth 96.8%, PE expands to 24.4
Base Case
$155.07
(+95%)
Market implied 96.8%, PE stable at 22.2
Bear Case
$53.58
(-33%)
Severe decline -20.0%, PE contracts to 18.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 12, 2026 1:43 PM ET
Data refreshes hourly during market hours. Next update: 2:43 PM
Data refreshes hourly during market hours. Next update: 2:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CBT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Specialty Chemicals Stocks
Top-rated stocks in Specialty Chemicals by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ECL
Ecolab Inc |
STRONG BUY
27 analysts |
$325 | 46 HOLD |
|
SHW
Sherwin-Williams Co |
BUY
28 analysts |
$391 | 47 HOLD |
|
LIN
Linde plc Ordinary Shares |
BUY
28 analysts |
$545 | 36 SELL |
|
APD
Air Products and Chemica… |
BUY
24 analysts |
$344 | 52 HOLD |
|
ALB
Albemarle Corp |
HOLD
28 analysts |
$173 | 48 HOLD |
